We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-20.00 | -1.02% | 1,934.00 | 1,925.00 | 1,926.00 | 1,956.00 | 1,919.00 | 1,955.00 | 145,039 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8653 | 22.25 | 4.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
07/11/2024 11:55 | 4* Hikma issued an encouraging trading update this morning. The Group is performing well and management continue to expect Group revenue to grow in the range of 6% to 8% and for core operating profit to be in the range of $700 million to $730 million in 2024, in line with previously upgraded guidance. All 3 segments - Injectables, Branded and Generics – are performing well...from WealthOracle wealthoracle.co.uk/d | martinmc123 | |
06/11/2024 17:43 | Good luck for tomorrow all.Decided to buy 5000 shares today in advance of the update. Lets see where this goes | semperlucrum | |
01/11/2024 08:51 | Not so much relevant to HIK tho as they only sell generics in North America I believe, non to EU market. Unless anyone knows otherwise. | dartboard1 | |
17/10/2024 13:00 | You can thank me for the rise as I sold out on Monday. Typical. Whilst I see all good things here, the market doesn't. I thought 25 pounds (interim 22 ) would be reasonable bit it struggles recently to hold above 20. I will be back as its still on my watch list. | hopeful holder | |
15/9/2024 16:15 | At some point they'll look to exit though, and given their shareholding, can only really do so via selling the whole co | adamb1978 | |
15/9/2024 13:52 | The Jordanian ownership definitely seems to give it a trading discount | dartboard1 | |
15/9/2024 09:21 | Jordanian run.Nobody trusts them. Unloved | robertball | |
10/9/2024 14:08 | I am a little perplexed here.. good performing company, significant improvements over last 12 months, expanding product range, increases in production capability and market potential yet the share price is being stubborn about reflecting that rise.Is this an unloved share or an unloved sector or has the market not picked up on the actual sand potentials here?Any views certainly invited. | hopeful holder | |
28/8/2024 15:39 | Cheers HH... I see ppl call out these trades and most of the time it's admin from the brokers rather than indicating anything coming ... hikma is a slow moving beast, it's slowly going about its business. Growing at low digits in revenue but divi is growing at a larger percentage which is key to long term holders... | dartboard1 | |
23/8/2024 13:57 | Apols for delay...The large uncrossing... appears little volume for a while and uncrossing trace unusually large.200k share is 4 million quid. In the context over previous closes it seemed awfully high and wondered if it indicated larger seller / buys around that may place up or down pressure.Whilst I think the share price should be higher, mr market currently disagrees despite a good recent update. | hopeful holder | |
13/8/2024 09:27 | Director disposal of 35,000 shares. Doesn't always mean much as he may need a new house, maybe divorce who knows. But this guy knows more about the financials than anyone at Hikma. He was CFO for the IPO and is now M&A VP ... | dartboard1 | |
12/8/2024 18:47 | What's your point, it was at the market price. Only reason to get excited would be if it was materially divergent from it...Not knocking, just interested in what you think it's telling you ... | dartboard1 | |
12/8/2024 15:57 | That's a big uncrossing trade at the end of the day. Over 200k in shares. | hopeful holder | |
07/8/2024 20:35 | Surely this should be closer to 2500. Expecting profit upgrade tomorrow | robertball | |
16/7/2024 10:56 | It's looking like top up time again.Not a stellar performer but a solid steady performer and even a quick 10% return is available here. | hopeful holder | |
03/7/2024 17:28 | I wish it would make its mind up as to if its going up or down! | hopeful holder | |
26/4/2024 09:00 | Yes, if you believe that they can grow earnings at mid to high single digit percentages, the multiple should be at least mid teens here. Think its one to just be patient on. Nice to see a little bit of life this morning | adamb1978 | |
25/4/2024 12:24 | Nothing exceptional in the tu - just confirms that it is relatively cheap as Adam notes. Odd initial negative reaction this morning, quickly reversed and those getting in early now have a quick gain. I would think that it should share in a general recovery of the sector if interest rates moderate. | boadicea | |
25/4/2024 06:48 | Decent trading statement this morning? PE of only c.11x for this year - feels like good risk/reward bet at these levels IMO | adamb1978 | |
22/3/2024 20:32 | This is the APH that has nearly halved in 6 months.Trading Hikma is proving profitable and still it's performed far better than your ongoing pumping of APH.I hope people research before buying anything that people are pumping on bulletin boards.. | hopeful holder | |
21/3/2024 13:00 | An XD related move of ~37p should not have resulted in a ~100p drop in the sp! I wonder whether it helped to trigger some stop-losses? - Ha-ha. | boadicea | |
21/3/2024 08:56 | Money moving to APH [LSE] , excellent profitable healthcare company | blackhorse23 | |
22/2/2024 07:13 | So a beat on all of those, but quite a lot of exceptional which need looking at - $129m of which opioid related. Agree div increase much more than expected. | 18bt | |
22/2/2024 07:06 | Dividend hike is chunky | robertball |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions